Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Confe...( Cystinosis Foundation Ireland...)

Cystinosis Foundation Ireland to Host Event June 27-28, 2008

NOVATO, Calif., June 23 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Ted Daley, President of Raptor's clinical division, will present at the Cystinosis Foundation Ireland's 5th International Cystinosis Conference to be held June 27-28, 2008 at the Hilton Hotel, Dublin City, Charlemont Place, Dublin 2, in Dublin, Ireland.

World experts in the field of Cystinosis and families affected by Cystinosis attending the event can discuss Mr. Daley's presentation between 3:45pm and 5:30pm in the conference hall on Friday, June 27, 2008, during the poster and round table session of the conference.

For more information on this event please visit: http://www.cystinosis.ie.

Cystinosis is an inborn metabolic error characterized by abnormal transport of cystine, an amino acid, out of the lysosomes. Symptom onset typically occurs within the first year after birth, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes. Failure to treat the disease can cause serious health consequences, including renal failure and resultant kidney transplant, growth failure, rickets, photophobia and blindness.

In collaboration with the University of California, San Diego ("UCSD"), supported by the Cystinosis Research Foundation ("CRF"), Raptor is developing a delayed-release version of cysteamine bitartrate ("DR Cysteamine") for the treatment of Cystinosis. Cysteamine bitartrate, a cystine-depleting agent, is the only Cystinosis treatment approved for sale by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMEA").

Although it can delay or prevent kidney transplant in Cystinosis patients, the current formulation of cysteamine bitartrate is
'/>"/>